FIM
BBIO icon

Fernwood Investment Management’s BridgeBio Pharma BBIO Stock Holding History

Fernwood Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$7.64M Buy
278,330
+16,595
+6% +$429K 2.66% 8
2024
Q3 		$6.66M Buy
261,735
+6,200
+2% +$163K 2.17% 10
2024
Q2 		$6.47M Buy
255,535
+10,415
+4% +$285K 2.01% 12
2024
Q1 		$7.58M Buy
245,120
+9,600
+4% +$326K 2.21% 8
2023
Q4 		$9.51M Sell
235,520
-100
-0% -$3K 3.13% 4
2023
Q3 		$6.21M Sell
235,620
-4,275
-2% -$121K 2.23% 9
2023
Q2 		$4.13M Buy
239,895
+2,920
+1% +$43.9K 1.46% 17
2023
Q1 		$3.93M Buy
236,975
+33,975
+17% +$396K 1.51% 16
2022
Q4 		$1.55M Sell
203,000
-1,550
-0.8% -$14.8K 0.64% 48
2022
Q3 		$2.03M Buy
204,550
+20,650
+11% +$215K 0.86% 30
2022
Q2 		$1.67M Buy
183,900
+11,575
+7% +$96.8K 0.72% 40
2022
Q1 		$1.75M Buy
172,325
+8,925
+5% +$91.6K 0.61% 48
2021
Q4 		$2.73M Buy
163,400
+5,502
+3% +$233K 0.89% 28
2021
Q3 		$7.4M Buy
157,898
+4,226
+3% +$227K 2.54% 7
2021
Q2 		$9.37M Buy
153,672
+2,587
+2% +$148K 3.1% 2
2021
Q1 		$9.31M Buy
151,085
+250
+0.2% +$16.4K 3.42% 2
2020
Q4 		$10.7M Buy
150,835
+7,000
+5% +$338K 4.23% 1
2020
Q3 		$5.4M Sell
143,835
-1,265
-0.9% -$39.8K 2.55% 9
2020
Q2 		$4.73M Buy
145,100
+41,850
+41% +$1.27M 2.34% 7
2020
Q1 		$2.99M Sell
103,250
-1,150
-1% -$35.7K 1.91% 11
2019
Q4 		$3.66M Buy
104,400
+9,200
+10% +$255K 1.75% 10
2019
Q3 		$2.04M Buy
+95,200
New +$2.63M 1.01% 30

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Fernwood Investment Management's BBIO Position: Q4 2024 in Review

Fernwood Investment Management increased its BridgeBio Pharma (BBIO) stake by 6.3% in Q4 2024, buying an estimated $429K and bringing the position to 278,330 shares worth $7.64M. The position accounts for 2.66% of the portfolio, ranked #8.

Fernwood Investment Management first reported a position in BBIO in Q3 2019 and has held it in 22 quarters since. The position peaked at $10.7M in Q4 2020. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

  • Fernwood Investment Management held 278,330 shares of BridgeBio Pharma worth $7.64M as of Q4 2024.
  • Fernwood Investment Management bought 16,595 BridgeBio Pharma shares in Q4 2024, an estimated $429K.
  • BridgeBio Pharma made up 2.66% of Fernwood Investment Management's portfolio in Q4 2024, its #8 holding.
  • Fernwood Investment Management first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 22 quarters since.
  • Fernwood Investment Management's BridgeBio Pharma position peaked at $10.7M in Q4 2020.
  • 263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Fernwood Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.